BioXcel Therapeutics

@BioXcel_Tx

A Clinical Stage Biopharmaceutical Company Advancing the Next Wave of Medicines in Immuno-Oncology & Neuroscience. (NASDAQ: BTAI)

Vrijeme pridruživanja: kolovoz 2017.

Tweetovi

Blokirali ste korisnika/cu @BioXcel_Tx

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @BioXcel_Tx

  1. BioXcel Therapeutics Announces Clearance of IND Application for for the Treatment of Withdrawal Symptoms.

    Poništi
  2. 4. velj

    Through our use of and , is identifying the next wave of across & Immuno- . This is our commitment on and every day. This year's theme-

    Poništi
  3. 3. velj
    Poništi
  4. 27. sij
    Poništi
  5. 7. sij

    Announces 1st Patient Enrollment in Phase 1b/2 study of for Acute Treatment of Agitation Associated with Dementia.

    Poništi
  6. 30. pro 2019.
    Poništi
  7. 11. pro 2019.

    Expands Study of into Multiple Advanced Solid Tumor Types. May Improve Response When Combined with . Trial Expands Studies of in and .

    Poništi
  8. 3. pro 2019.
    Poništi
  9. 27. stu 2019.
    Poništi
  10. 26. stu 2019.

    Our CEO, Dr. Vimal Mehta, will present at the @PiperJaffrayCo 31st Annual Healthcare Conference in New York, Tuesday, Dec. 3, 2019, from 11:50 am to 12:10 pm ET. A live webcast will be accessible through the company's website .

    Poništi
  11. 21. stu 2019.

    We're excited to see our lab featured on News 8! Thank you and ! is using to develop a new therapy for . Check out the story here!

    Poništi
  12. 13. stu 2019.

    Our CFO, Richard Steinhart, was thrilled to share his thoughts with Jack Sweeney on 's use of in drug development. Richard reveals why is a standout in a crowded space. Check out Richard's interview here!

    Poništi
  13. 11. stu 2019.

    Today, and every day, we honor all those who’ve answered the call to serve this great nation. Thank you for your bravery, service, and tremendous sacrifice from . Happy !

    Poništi
  14. 8. stu 2019.

    is the 2nd leading cause of death in men? is dedicated to raising awareness for . is teaming w/ to evaluate in combination w/ to treat . .

    Poništi
  15. 30. lis 2019.

    Our CEO and founder Dr. Vimal Mehta shared 's exciting news with . is developing (such as watch) to help combat .

    Poništi
  16. proslijedio/la je Tweet
    26. lis 2019.

    Dr. Vince O’Neill of discusses safety and tolerability results from a phase 1b study testing BXCL701, a novel inhibitor of DPP8/9 / FAP, in combination with pembrolizumab in small cell/ neuroendocrine .

    Poništi
  17. 24. lis 2019.

    Our sister company took a seat on 's panel discussing in drug development. CEO and founder Krishnan Nandabalan's & platform is transforming .

    Poništi
  18. 24. lis 2019.
    Poništi
  19. 10. lis 2019.
    Poništi
  20. 10. lis 2019.

    continues to follow and support in his courageous fight with stage 4 . We commend his grace and strength. is a triple combination in development with for .

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·